[Clinical evaluation of ifosfamide in the treatment of malignant neoplasms].
D000477:Alkylating Agents / Q000627:therapeutic use*; D002273:Carcinogens / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D003498:Cyclic P-Oxides / Q000627:therapeutic use*; D004341:Drug Evaluation; D004361:Drug Tolerance; D005021:Ethylamines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D010078:Oxazines / Q000627:therapeutic use*
D000477:Alkylating Agents; D002273:Carcinogens; D003498:Cyclic P-Oxides; D005021:Ethylamines; D010078:Oxazines
Ocena kliniczna ifosfamidu w leczeniu nowotworów złośliwych.